• Innate Pharma initiated lacutamab’s TELLOMAK-3 Phase 3 trial in cutaneous T-cell lymphoma, with first patient enrollment expected in Q1 2027.
• The program targets potential US accelerated approval in Sézary syndrome in H1 2028, based on Phase 2 data.
• Sobi paid $75 million upfront for the partnership; additional option-related, regulatory and commercial milestones could reach $465 million.
• Monalizumab’s PACIFIC-9 Phase 3 trial is scheduled to deliver high-level data in the first half of 2027.
• IPH4502 Phase 1 data are expected in the second half of 2026, with preliminary objective responses observed in solid tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.